Skip to main content

RVL Pharmaceuticals plc

RVLPDelisted Nov 20, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001739426

RVL Pharmaceuticals plc was delisted on Nov 20, 2023; its insiders filed their last Form 4 on Oct 23, 2023; 32 institutions reported holding it in 13F filings for Q3 2023, worth $1.57M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by RVL Pharmaceuticals plc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for RVL Pharmaceuticals plc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for RVL Pharmaceuticals plc
NameTitleLast reported holdingLast filingFilings, past year
Harsaul Foundation10% Owner4,941,101IndirectOct 23, 20230
Altchem Ltd10% Owner4,941,101Oct 23, 20230
Orbit Co-Invest A-1 LLC10% Owner4,941,101Oct 23, 20230
Avista Healthcare Partners, L.P.10% Owner0IndirectAug 17, 20230
Avista Healthcare Partners GP, Ltd.10% Owner0IndirectAug 17, 20230
Lask AlisaDirector112,557Aug 14, 20230
Cowan Gregory LDirector90,055Jul 11, 20230
DeBiasi Michael J.Director40,000Jul 11, 20230
Schaub JamesEVP and COO524,835May 22, 20230
Klein ChristopherGeneral Counsel & Secretary180,573May 22, 20230
Avista Capital Partners III GP, L.P.10% Owner0IndirectJan 30, 20230
Orbit Co-Invest III LLC10% Owner0IndirectJan 30, 20230
Burgstahler David FDirector, 10% Owner0IndirectJan 30, 20230
Venkataraman SriramDirector, 10% Owner0IndirectJan 30, 20230
Markison Brian AChief Executive Officer2,976,020Aug 9, 20220
deVries Tina MarieEVP, Research & Development136,141May 20, 20220
Einhorn Andrew J.Chief Financial Officer141,473Jan 26, 20220
Weiss Fred GDirector118,466Sep 3, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 23, 2023 (view filing)4:23 PM ETOct 19-204 daysHarsaul Foundation10% OwnerSSale−14.1M$0.0411−$580.1K−74.1%4.94M after2 lotsDuplicate filing
Oct 23, 2023 (view filing)1:06 PM ETOct 19-204 daysAltchem Ltd and 1 other10% OwnerSSale−14.1M$0.0411−$580.1K−74.1%4.94M after2 lots
Oct 20, 2023 (view filing)3:59 PM ETOct 182 daysHarsaul Foundation10% OwnerSSale−3.42M$0.0646−$221.0K−15.2%19.1M afterDuplicate filing
Oct 20, 2023 (view filing)1:36 PM ETOct 182 daysAltchem Ltd and 1 other10% OwnerSSale−3.42M$0.0646−$221.0K−15.2%19.1M after
Aug 9, 2022 (view filing)5:18 PM ETAug 81 dayAvista Capital Partners III GP, L.P. and 3 others10% OwnerPPurchase+8.00M$1.55+$12.4M+50.9%23.7M afterDuplicate filing
Aug 9, 2022 (view filing)Aug 81 daySchaub JamesEVP and COOPPurchase+150.0K$1.55+$232.5K+38.5%540.0K after
Aug 9, 2022 (view filing)Aug 81 dayMarkison Brian AChief Executive OfficerPPurchase+850.0K$1.55+$1.32M+40.0%2.98M after
Aug 9, 2022 (view filing)Aug 81 dayBurgstahler David FDirector, 10% OwnerPPurchase+8.00M$1.55+$12.4M+50.9%23.7M afterDuplicate filing
Aug 9, 2022 (view filing)Aug 81 dayVenkataraman SriramDirector, 10% OwnerPPurchase+8.00M$1.55+$12.4M+50.9%23.7M after
Dec 20, 2021 (view filing)Dec 164 daysSchaub JamesEVP and COOPPurchase+93.8K$1.07+$100.4K+30.1%405.9K after